Opthea

OPTPhase 3

Melbourne, AustraliaFounded 2007opthea.com

Opthea is a publicly traded biotech dedicated to addressing significant unmet needs in retinal vascular diseases. Its core innovation is sozinibercept (OPT-302), a soluble VEGF-C and VEGF-D inhibitor that, when combined with standard-of-care anti-VEGF-A drugs, aims to provide superior efficacy by blocking a broader spectrum of angiogenic pathways. The company's strategic direction is centered on completing its Phase 3 program for wet AMD and DME, with the goal of establishing a new standard of care. Key achievements include positive Phase 2b data and the initiation of two global Phase 3 trials (COAST and ShORe).

Market Cap

$580M

Founded

2007

Employees

11-50

Focus

Biotech

AI Company Overview

Technology Platform

Develops soluble VEGF receptor 'trap' proteins that inhibit specific vascular endothelial growth factors (VEGF-C and VEGF-D) to treat retinal vascular diseases by blocking angiogenic pathways not targeted by current standard-of-care therapies.

Pipeline Snapshot

5 drugs in pipeline, 2 in Phase 3

Drug	Indication	Stage
2.0 mg OPT-302 + 2.0 aflibercept	Neovascular Age-related Macular Degeneration	Phase 3
2.0 mg OPT-302 + 0.5 mg ranibizumab	Neovascular Age-related Macular Degeneration	Phase 3
OPT-302 + ranibizumab	Neovascular Age-related Macular Degeneration	Phase 2
Aflibercept + OPT-302	Diabetic Macular Edema	Phase 1/2
OPT-302 + Lucentis™	Eye Diseases	Phase 1

Funding History

Total raised: $30M

Grant$10MAustralian GovernmentJan 1, 2020

IPO$20MUndisclosedJan 1, 2015

Opportunities

The primary growth opportunity is the successful approval and commercialization of sozinibercept as a first-in-class combination therapy for wet AMD and DME, targeting a multi-billion dollar market.

Additional opportunities include exploring the drug's efficacy in other retinal vascular diseases and geographic expansion.

A strategic partnership or acquisition by a larger pharma company is a likely avenue for value realization.

Risk Factors

Key risks include clinical trial failure in Phase 3, regulatory hurdles, intense competition from established and new therapies, potential difficulty in achieving market adoption, and dependence on a single clinical asset.

The company also faces financial risk related to the high cost of late-stage trials and potential future dilution.

Competitive Landscape

Opthea's main competitors are large pharmaceutical companies with dominant anti-VEGF-A drugs (Regeneron, Roche, Novartis) and newer entrants like Roche's Vabysmo. Its differentiation lies in its unique VEGF-C/D mechanism aimed at improving upon the efficacy ceiling of current monotherapies. Success requires demonstrating clear clinical superiority in head-to-head combination trials.

Publications

Pipeline